Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Arena's Lorcaserin Gigantic Market

|Includes:Arena Pharmaceuticals, Inc. (ARNA)

Arena's Lorcaserin Gigantic Market:

Ralph Ryback MD

Lorcaserin-four other significant markets have been overlooked

Arena's Lorcaserin Gigantic Market: -----The last few months have focused on comparisons of Arena's Lorques (lorcaserin) and Vivus's Qnexa and the financial extrapolations thereof. Lorques is a safe weight loss approach for all women whether of child bearing age (without the fear of cleft palate in their newborns) and all others without the fear of cardiac (six heart attacks in the Qnexa studies) or memory issues. But in this unbalanced comparison which clearly favors Lorques's safety, four other possible significant markets have been overlooked. (1) Lorques qualifies as a first line diabetic medication in its beneficial effects on blood glucose levels (minus 27 points) and hemoglobin A1c (minus 0.9 points). - (2) A third of our children and teens are overweight or obese. They are at high risk to develop Type 2 diabetes or "diabesity". When I was an intern in medicine at Boston City Hospital, teenage diabetics were so rare that Residents would call me over to interview them. Now there are adolescent clinics in all large cities. A study published online on Sunday, April 29, by the New England Journal of Medicine of 699 obese and overweight teens found 1 in 5 suffered serious complications such as out of control blood sugar and hospitalization. Almost half failed treatment within a few years with metformin, Avandia, insulin, diet, or combinations thereof. Lorques is positioned as a safe alternative for both weight loss and diabetic management is this vulnerable population. The National Institutes of Health (NIH) promotes the study of new medication thru research grants in children and adolescents. (3). ---The biggest preventable public health problem in the U.S. (obesity is neck and neck) is Smoking! There is significant research data that 5HT 2c receptor agonists (i.e. stimulators) modulate nicotine dependence and use (e.g. J. Pharmacol. Exp. Ther. 2011 (3) 890-6; Prog. Brain Res. 2008; 172: 361-83; Psychopharmacology (Berl) 20001; 157: 292-8; Trends Pharmacol. Sci. 2001; 22 (5):229-32). Lorcaserin is a 5H T 2c agonist which in both short and long term (two weeks) administration in Sprague Dawley rats significantly reduced nicotine self-administration. If Lorques can reduce smoking in Americans it will open up at least a one billion dollar market, particularly since many women, and men, are loathed to stop smoking since they fear weight gain. (4)---The mesocortical limbic dopamine system (MLDA) is under inhibitory control thru stimulation of the 5HT 2c receptors. The MLDA is centrally involved in depression, addiction and schizophrenia. This opens the door to lorques's possible application in these areas and a market capitalization no one has dared to mention.

Stocks: ARNA